Anders Lindfors

Learn More
Hereditary angioedema (HAE) due to C1 inhibitor deficiency is a rare disease characterized by attacks of edema, known to impact quality of life (QoL). This study investigates the burden of HAE in Swedish patients, both children and adults. We used a retrospective registry study of Swedish patients with HAE, captured by the Sweha-Reg census. Data were(More)
BACKGROUND The importance of acquiring comprehensive epidemiological and clinical data on hereditary angioedema has increasingly caught the attention of physicians and scientists around the world. The development of networks and creation of comprehensive policies to improve care of people suffering from rare diseases, such as hereditary angioedema, is a(More)
AIM Few studies have been published on children with hereditary angioedema (HAE), an autosomal dominant disease caused by mutations on chromosome 11. This study explored various aspects of the disease in the Swedish paediatric population. METHODS A retrospective questionnaire was sent to all 36 Swedish children known to have HAE, and a physician carried(More)
BACKGROUND Health-related quality of life (HR-QoL) is impaired in patients with hereditary angioedema (HAE) but has notyet been satisfactorily described. OBJECTIVE To study HR-QoL in patients with HAE by combining different HR-QoL instruments with disease activity assessment. METHODS All adults in the Swedish HAE registry were invited to take part in(More)
Hereditary angioedema (HAE) is rare, disabling and sometimes life-threatening. The aim of this study is to describe its prevalence, symptomatology and treatment in Sweden. A total of 146 patients were identified; 110 adults and 36 children with HAE type I (n = 136) or II (n = 10), giving a minimal HAE prevalence of 1.54/100,000. All patients received a(More)
s from the 10th C1-inhibitor deficiency workshop Budapest, Hungary. 18–21 May 2017 © The Author(s) 2017. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give(More)
  • 1